Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials - Guttman-Yassky, E; Teixeira, HD; Simpson, EL (Lancet, 2021)
et al.